본문 바로가기
KERD
논문KCI 등재

C-Reactive Protein a Promising Biomarker of COVID-19 Severity

Muntaha Fazal
대한임상검사과학회 (Korean Society for Clinical Laboratory Science)|2021.09|대한임상검사과학회지 (Korean Journal of Clinical Laboratory Science)|제53권 제3호|pp. 201-207|DOI 10.15324/kjcls.2021.53.3.201

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

COVID-19SeverityC-reactive protein
주제분류기타자연과학

초록

The 2019 coronavirus outbreak poses a threat to scientific, societal, financial, and health resources. The complex pathogenesis of severe acute respiratory syndrome coronavirus centers on the unpredictable clinical progression of the disease, which may evolve abruptly and result in critical and life-threatening clinical complications. Effective clinical laboratory biomarkers that can classify patients according to risk are essential for ensuring timely treatment, and an analysis of recently published studies found cytokine storm and coagulation disorders were leading factors of severe COVID-19 complications. The following inflammatory, biochemical, and hematology biomarkers markers have been identified in COVID-19 patients; neutrophil to lymphocyte ratio, c-reactive protein, procalcitonin, urea, liver enzymes, lactate dehydrogenase, serum amyloid A, cytokines, d-dimer, fibrinogen, ferritin, troponin, creatinine kinase, and lymphocyte, leukocyte, and platelet counts. These factors are predictors of disease severity and some are involved in the pathogenesis of COVID-19. CRP is an acute-phase, non-specific serological biomarker of inflammation and infection and is related to disease severities and outcomes. In the present study, CRP levels were found to rise dramatically among COVID-19 patients, and our findings suggest CRP could be utilized clinically to predict COVID-19 prognosis and severity even before disease progression and the manifestation of clinical symptoms.

Abstract

The 2019 coronavirus outbreak poses a threat to scientific, societal, financial, and health resources. The complex pathogenesis of severe acute respiratory syndrome coronavirus centers on the unpredictable clinical progression of the disease, which may evolve abruptly and result in critical and life-threatening clinical complications. Effective clinical laboratory biomarkers that can classify patients according to risk are essential for ensuring timely treatment, and an analysis of recently published studies found cytokine storm and coagulation disorders were leading factors of severe COVID-19 complications. The following inflammatory, biochemical, and hematology biomarkers markers have been identified in COVID-19 patients; neutrophil to lymphocyte ratio, c-reactive protein, procalcitonin, urea, liver enzymes, lactate dehydrogenase, serum amyloid A, cytokines, d-dimer, fibrinogen, ferritin, troponin, creatinine kinase, and lymphocyte, leukocyte, and platelet counts. These factors are predictors of disease severity and some are involved in the pathogenesis of COVID-19. CRP is an acute-phase, non-specific serological biomarker of inflammation and infection and is related to disease severities and outcomes. In the present study, CRP levels were found to rise dramatically among COVID-19 patients, and our findings suggest CRP could be utilized clinically to predict COVID-19 prognosis and severity even before disease progression and the manifestation of clinical symptoms.

참고문헌 (52)

  1. "Pneumonia of unknown cause—China" (2020)[URL]
  2. Lippi G, "Coronavirus disease 2019(COVID-19) : the portrait of a perfect storm", Ann Transl Med, 8, pp.497~ (2020)[DOI]
  3. Schulman S., "Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism", Semin Thromb Hemost, 46, pp.772~776 (2020)[DOI]
  4. Thachil J, "SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism?", Semin Thromb Hemost, 46, pp.777~780 (2020)[DOI]
  5. Levi M, "Coronavirus disease 2019 coagulopathy : disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both", Semin Thromb Hemost, 46, pp.781~784 (2020)[DOI]
  6. Hu B, "The cytokine storm and COVID-19", J Med Virol, 93, pp.250~256 (2021)[DOI]
  7. Kwaan HC, "Coronavirus disease 2019 : The role of the fibrinolytic system from transmission to organ injury and sequelae", Semin Thromb Hemost, 46, pp.841~844 (2020)[DOI]
  8. Favaloro EJ, "Recommendations for minimal laboratory testing panels in patients with COVID-19 : potential for prognostic monitoring", Semin Thromb Hemost, 46, pp.379~382 (2020)[DOI]
  9. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)[DOI]
  10. Giuseppe Lippi, "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis", Clinica Chimica Acta, 506, pp.145~148 (2020), Elsevier BV[DOI]
  11. Thachil J, "ISTH interim guidance on recognition and management of coagulopathy in COVID-19", J Thromb Haemost, 18, pp.1023~1026 (2020)[DOI]
  12. Han H, "Prominent changes in blood coagulation of patients with SARS-CoV-2 infection", Clin Chem Lab Med, 58, pp.1116~1120 (2020)[DOI]
  13. Lippi G, "Laboratory abnormalities in patients with COVID-2019 infection", Clin Chem Lab Med, 58, pp.1131~1134 (2020)[DOI]
  14. Tang N, "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia", J Thromb Haemost, 18, pp.844~847 (2020)[DOI]
  15. Chen W, "Plasma CRP level is positively associated with the severity of COVID-19", Ann Clin Microbiol Antimicrob, 19, pp.18~ (2020)[DOI]
  16. Huang J, "Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity", J Med Virol, 92, pp.2152~2158 (2020)[DOI]
  17. Han Y, "Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients : a retrospective and observational study", Aging(Albany NY), 12, pp.11245~11258 (2020)[DOI]
  18. Cheng L, "Ferritin in the coronavirus disease 2019(COVID-19) : a systematic review and meta-analysis", J Clin Lab Anal, 34, pp.e23618~ (2020)[DOI]
  19. Liu Y, "Neutrophilto-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19", J Infect, 81, pp.e6~e12 (2020)[DOI]
  20. Zhao Q, "Lymphopenia is associated with severe coronavirus disease 2019(COVID-19)infections : a systemic review and meta-analysis", Int J Infect Dis, 96, pp.131~135 (2020)[DOI]
  21. Hamed Akbari, "The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis", Life Sciences, 258, pp.118167~ (2020), Elsevier BV[DOI]
  22. Hu R, "Procalcitonin levels in COVID-19 patients", Int J Antimicrob Agents, 56, pp.106051~ (2020)[DOI]
  23. Sproston NR, "Role of C-Reactive protein at sites of inflammation and infection", Front Immunol, 9, pp.754~ (2018)[DOI]
  24. Du Clos TW, "Function of C-reactive protein", Ann Med, 32, pp.274~278 (2000)[DOI]
  25. Bhardwaj N, "C-reactive protein as a prognostic marker of Plasmodium falciparum malaria severity", J Vector Borne Dis, 56, pp.122~126 (2019)[DOI]
  26. Vuong NL, "C-reactive protein as a potential biomarker for disease progression in dengue : a multi-country observational study", BMC Med, 18, pp.35~ (2020)[DOI]
  27. de Souza Pires-Neto O, "Hepatic TLR4, MBL and CRP gene expression levels are associated with chronic hepatitis C", Infect Genet Evol, 80, pp.104200~ (2020)[DOI]
  28. Li X, "Predictive indicators of severe COVID-19 independent of comorbidities and advanced age : a nested case-control study", Epidemiol Infect, 148, pp.e255~ (2020)[DOI]
  29. Liu F, "Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19", J Clin Virol, 127, pp.104370~ (2020)[DOI]
  30. Mueller AA, "Inflammatory biomarker trends predict respiratory decline in COVID-19 patients", Cell Rep Med, 1, pp.100144~ (2020)[DOI]
  31. Ahnach M, "C-reactive protein as an early predictor of COVID-19 severity", J Med Biochem, 39, pp.500~507 (2020)[DOI]
  32. Sadeghi-Haddad-Zavareh M, "C-reactive protein as a prognostic indicator in COVID-19 patients", Interdiscip Perspect Infect Dis, 2021, pp.5557582~ (2021)[DOI]
  33. Stringer D, "The role of C-reactive protein as a prognostic marker in COVID-19", Int J Epidemiol, 50, pp.420~429 (2021)[DOI]
  34. Poggiali E, "Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients", Clin Chim Acta, 509, pp.135~138 (2020)[DOI]
  35. Shang W, "The value of clinical parameters in predicting the severity of COVID-19", J Med Virol, 92, pp.2188~2192 (2020)[DOI]
  36. Liu SL, "Expressions of SAA, CRP, and FERR in different severities of COVID-19", Eur Rev Med Pharmacol Sci, 24, pp.11386~11394 (2020)[DOI]
  37. Bergantini L, "Prognostic bioindicators in severe COVID-19patients", Cytokine, 141, pp.155455~ (2021)[DOI]
  38. Xue G, "Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19", Int Immunopharmacol, 89, pp.107065~ (2020)[DOI]
  39. Gökhan Aksel, "Early predictors of mortality for moderate to severely ill patients with Covid-19", The American Journal of Emergency Medicine, 45, pp.290~296 (2021), Elsevier BV[DOI]
  40. Wang Z, "Identification of risk factors for in-hospital death of COVID-19 pneumonia –lessions from the early outbreak", BMC Infect Dis, 21, pp.113~ (2021)[DOI]
  41. Ullah W, "Predictability of CRP and D-Dimer levels for in-hospital outcomes and mortality of COVID-19", J Community Hosp Intern Med Perspect, 10, pp.402~408 (2020)[DOI]
  42. Smilowitz NR, "C-reactive protein and clinical outcomes in patients with COVID-19", Eur Heart J, 42, pp.2270~2279 (2021)[DOI]
  43. Liu YP, "Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia : a retrospective cohort study", Ann Transl Med, 8, pp.635~ (2020)[DOI]
  44. Yamada T, "Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019(COVID-19) : A systematic review and meta-analysis", Clin Chim Acta, 509, pp.235~243 (2020)[DOI]
  45. Tan C, "C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early", J Med Virol, 92, pp.856~862 (2020)[DOI]
  46. Keddie S, "Laboratory biomarkers associated with COVID-19 severity and management", Clin Immunol, 221, pp.108614~ (2020)[DOI]
  47. Wang G, "C-reactive protein level may predict the risk of COVID-19 aggravation", Open Forum Infect Dis, 7, pp.ofaa153~ (2020)[DOI]
  48. Kushner I, "What does minor elevation of c-reactive protein signify?", Am J Med, 119, pp.166~ (2006)[DOI]
  49. Xu X, "Analysis of inflammatory parameters and disease severity for 88hospitalized COVID-19 patients in Wuhan, China", Int J Med Sci, 17, pp.2052~2062 (2020)[DOI]
  50. Lau ES, "Sex differences in inflammatory markers in patients hospitalized with COVID-19 infection : insights from the MGH COVID-19 patient registry", PLoS One, 16, pp.e0250774~ (2021)[DOI]
  51. Laguna-Goya R, "IL-6-based mortality risk model for hospitalized patients with COVID-19", J Allergy Clin Immunol, 146, pp.799~807 (2020)[DOI]
  52. Wang L, "C-reactive protein in the early stages of COVID-19", Med Mal infect, 50, pp.332~334 (2020)[DOI]

이 간행물의 다른 논문 (9건)

Status of Kidney Function in Hospitalised COVID-19 Patients in the Southern Gyeonggi Province, South KoreaHyun Ho Sung, Sun-Gyu Kimpp. 208-216Ciprofloxacin 내성 대장균에서 Sequence Type과 Fluoroquinolone 내성의 분석조혜현pp. 217-2242015∼2020년 동안 인천 지역 단일기관에서의 비결핵항산균 분포 및 항균제 내성률Jiwoo Kim, Jehyun Koo, Kyungcheol Song, Jayoung Kim, 이혜영, 주효진, 박현환pp. 225-232유방 보존술 중 절제면 동결절편검사의 질 향상에 관한 연구Byung-Il Choi, Su-Sie Chinpp. 233-240대한민국 고혈압 성인에서 아스파르트산 아미노전이효소/알라닌 아미노전이효소 비율과 맥압의 관련성윤현pp. 241-248
원문 보기